Exploring Multidimensional Risk Factors Associated with Local Adverse Reactions to Subcutaneous Immunoglobulin Therapy: Insights from a Nationwide Multicenter Study

<b>Background/Objectives</b>: Subcutaneous immunoglobulin (SCIg) is a well-established alternative to intravenous immunoglobulin (IVIg) in patients with primary (PID) and secondary immunodeficiency (SID), with demonstrated benefits in safety and quality of life. However, its implementation remains l...

Полное описание

Библиографические подробности

Главные авторы:	Sandra Martínez Mercader, Victor Garcia-Bustos, Pedro Moral Moral, Carmen Martínez Buenaventura, Elisa Escudero Vergara, María Carmen Montaner Bosch, Héctor Balastegui-Martín, Sonia Galindo Maycas, Miriam González Amores, Noemí Gimenez Sanz, Marian Escobar Palazón, María Moreno Mulet, Ignacio Campanero Carrasco, Alicia López, Carlos Daniel Hernández Ruiz, Laura Ruiz-López, Rocío Guzmán Guzmán, Marta Dafne Cabañero-Navalon
Формат:	Artigo
Язык:	Inglês
Опубликовано:	MDPI AG 2025-08-01
Серии:	Biomedicines
Предметы:	common variable immunodeficiency (CVID) immunoglobulin replacement therapy (IgRT) subcutaneous immunoglobulin (SCIg) intravenous immunoglobulin (IVIg) real-world evidence
Online-ссылка:	https://www.mdpi.com/2227-9059/13/8/1991
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!